Baptista Alexandre, Marreiros Ana, Macedo Ana, Coelho André
Medicine and Biomedical Sciences, Universidade do Algarve, Faro, PRT.
Health and Technology Research Center, Instituto Politécnico de Lisboa, Lisboa, PRT.
Cureus. 2024 Jul 1;16(7):e63636. doi: 10.7759/cureus.63636. eCollection 2024 Jul.
Background Drugs are a frequent cause of nephrotoxicity, especially in the context of acute kidney disease (AKD), with a significant number of cases being drug-associated. The WHO's VigiBase is a powerful tool for identifying drugs described and associated with the development of AKD. Methods We retrieved data from the period 1968 to 2022 regarding notifications of adverse drug reactions (ADR). The extracted medications were evaluated for their nephrotoxicity based on the bibliographic score (BS) developed through pre-selected references. The main medications involved were classified as 'non-nephrotoxic', 'potentially nephrotoxic', and 'nephrotoxic'. We utilized the IC and reporting odds ratio (ROR) disproportionality indexes to study the relationship between medications and the odds of being included in an AKD notification. Results During the period, a total of 33,932,051 notifications were obtained, revealing 435,677 cases related to drug-associated AKD following MedDRA term filtering, predominantly affecting males aged 45-64. We identified 8,991 active ingredients or suspected combinations associated with AKD development, with the ATC class A - Alimentary Tract and Metabolism being the most frequently described. Among the medications most strongly associated with this phenotype, classes J and N stood out. Among the most notable medications collected, 8.3% were classified as "non-nephrotoxic," 16.7% as "potentially nephrotoxic," and 75% as "known nephrotoxic." Notable active ingredients included cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil (IC 8.7; ROR 786.96), inotersen (IC 7.7; ROR 604.57), emtricitabine + tenofovir disoproxil (IC 7.9; ROR 432.36), esomeprazole (IC 6.8; ROR 184.23), and pantoprazole (IC 6.3; ROR 109.86), with proton pump inhibitors dominating the top four positions among the most frequently involved medications. Conclusion AKD is a frequent adverse reaction in VigiBase, with a significantly high reported mortality rate. Evaluation of the notifications revealed medications with a high disproportionality index and a strong association with AKD. We also highlight the potential nephrotoxic role of less suspected medications. This study emphasizes the need to consider AKD as a condition potentially associated with iatrogenic etiology, highlighting various medications and their respective involvement in the various possible manifestations of AKD.
背景 药物是肾毒性的常见原因,尤其是在急性肾脏病(AKD)的情况下,大量病例与药物相关。世界卫生组织的药物不良反应数据库(VigiBase)是识别与AKD发生相关的药物的有力工具。方法 我们检索了1968年至2022年期间关于药物不良反应(ADR)报告的数据。根据通过预先选定的参考文献制定的文献评分(BS)对提取的药物进行肾毒性评估。所涉及的主要药物被分类为“非肾毒性”、“潜在肾毒性”和“肾毒性”。我们利用信息成分(IC)和报告比值比(ROR)不成比例指数来研究药物与被纳入AKD报告的可能性之间的关系。结果 在该期间,共获得33932051份报告,经MedDRA术语筛选后,发现435677例与药物相关的AKD病例,主要影响45 - 64岁的男性。我们确定了8991种与AKD发生相关的活性成分或疑似组合,其中ATC分类A - 消化道及代谢类是描述最频繁的。在与该表型关联最强的药物中,J类和N类最为突出。在所收集的最显著药物中,8.3%被分类为“非肾毒性”,16.7%为“潜在肾毒性”,75%为“已知肾毒性”。显著的活性成分包括考比司他+埃替拉韦+恩曲他滨+替诺福韦酯(IC 8.7;ROR 786.96)、inotersen(IC 7.7;ROR 604.57)、恩曲他滨+替诺福韦酯(IC 7.9;ROR 432.36)、埃索美拉唑(IC 6.8;ROR 184.23)和泮托拉唑(IC 6.3;ROR 109.86),质子泵抑制剂在最常涉及的药物中占据前四位。结论 AKD是VigiBase中常见的不良反应,报告的死亡率显著较高。对报告的评估揭示了不成比例指数高且与AKD关联强烈的药物。我们还强调了较少被怀疑的药物的潜在肾毒性作用。本研究强调需要将AKD视为一种可能与医源性病因相关的病症,突出了各种药物及其在AKD各种可能表现中的各自作用。